ABSTRACT
Background: A secondary cause can be found in up to one third of women with osteoporosis, potentially modifying their therapeutic approach. Aim: To determine the prevalence of secondary causes and risk factors for decreased bone mineral density (BMD) and osteoporosis. Material and Methods: We included postmenopausal women with a diagnosis of osteoporosis or low BMD who consulted for the first time in an endocrinology clinic between October 2018 and March 2020. A complete medical history, physical examination and a standardized laboratory assessment to identify secondary causes were performed. Results: During the study period, 114 women were evaluated, 30 of them with low BMD and 84 with osteoporosis. After obtaining a medical history and a structured laboratory screening, at least one secondary cause was found in 50% of patients with osteoporosis and in 67% of those with low BMD. Most patients with no identified secondary cause had at least one risk factor for fragility fractures. Conclusions: A structured evaluation that includes medical history and standardized laboratory study in postmenopausal women with osteoporosis or low BMD, is a valuable tool to identify secondary causes of osteoporosis.
ABSTRACT
Hypophosphatemia is a relatively frequent and a potentially serious adverse drug effect. Clinically it is characterized by bone pain and muscle weakness. There are several mechanisms by which a drug can induce hypophosphatemia and they can be classified according to whether or not they are mediated by an excess of Fibroblast Growth Factor 23 (FGF23). We report two patients with the condition: (i) A 49-year-old woman with Chronic Myeloid Leukemia (CML) and gastric sleeve surgery at 46 years of age. After receiving intravenous carboxymaltose iron in one occasion due to refractory anemia, she developed symptomatic hypophosphatemia. Urinary phosphate losses associated with high FGF23 levels were confirmed. Plasma phosphate returned to normal values 90 days after the iron administration. (ii) A 40-year-old man with a history of CML in whom imatinib was started. He developed symptomatic hypophosphatemia due to non FGF23-mediated hyperphosphaturia. As treatment with imatinib could not be interrupted, hypophosphatemia and its symptoms resolved with oral phosphate intake. These cases illustrate the importance of recognizing and treating drug-induced hypophosphatemia in a timely manner, and thus avoid the morbidity associated with this entity.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Hypophosphatemia , Phosphates , Administration, Intravenous , Imatinib Mesylate , IronABSTRACT
El trastorno de déficit atencional con hiperactividad (TDAH) constituye uno de los cuadros de mayor prevalencia durante la niñez. El presente trabajo se focalizó en evaluar si el Test de Rendimiento Continuo de Conners era capaz de discriminar entre niños con y sin TDAH diagnosticados por el docente. Se conformó una muestra no probabilística de 30 niños escolares (15 clínicos y 15 normales) a través de la aplicación del cuestionario de atención. Todos los niños completaron la aplicación del test computarizado de Conners. Se observaron diferencias significativas entre la muestra normal y clínica. Todos los niños seleccionados como normales no encajaron el perfil clínico. Solo el 50% de los casos considerados con TDAH encajaron el perfil clínico. Se analizan las implicancias del sobre/diagnóstico del trastorno.
Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent disorder during childhood. The present study aimed to evaluate if the Conners Continous Performance Test was able to discriminate among ADHD and normal children completed the Conners computarized test. Significant differences between normal and clinical sample were found. All children selected as normal did not fit the clinical profile. Only 50% of the children considered as having ADHD fit the clinical profile. Implications for the issue of overdiagnosis of the disorder are discussed.
Subject(s)
Humans , Male , Female , Child , Adolescent , Attention Deficit Disorder with Hyperactivity/diagnosis , Neuropsychological Tests , Psychomotor Performance , Attention Deficit Disorder with Hyperactivity/psychology , ChileABSTRACT
La alta frecuencia de los trastornos depresivos en el mundo y las altas tasas reportadas durante el pre y postparto, alertan sobre la necesidad de profundizar en la comprensión de la depresión materna perinatal y sus repercusiones psicológicas en la madre y el niño/a. Se describen y analizan sus características, los factores protectores y de riesgo, los principales efectos en el vínculo madre-bebé, el desarrollo infantil y la identidad materna a partir de una revisión de la literatura existente. Se reflexiona también sobre las implicancias clínicas de este trastorno, las alternativas de tratamiento y los desafíos actuales para su abordaje psicoterapéutico integral, considerando los distintos aspectos de la matriz relacional de la díada madre-hijo/a en interacción...
The high frequency of the Depressive Disorder in the world and the high reported rates during the prenatal and postpartum period warm about the necessity of studying the perinatal maternal depression, and its psychological impact on the mother and her child. It is described and analyzed their features, risk and protective factors, the main effects on the mother-baby bond and the child development and maternal identity, based on a literature review. It also reflects about the clinical implications of the disorder, the alternatives of existing treatment, and the current challenges for an integral psychotherapeutic approach, considering different aspects of the relational matrix of the interacting dyad...